Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,190.00
Bid: 12,210.00
Ask: 12,214.00
Change: 162.00 (1.35%)
Spread: 4.00 (0.033%)
Open: 12,036.00
High: 12,214.00
Low: 12,024.00
Prev. Close: 12,028.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

India's vaccine output likely to fall short of target, sources say

Thu, 20th May 2021 13:14

By Neha Arora and Krishna N. Das

NEW DELHI, May 20 (Reuters) - India's output of COVID-19
shots for August-December is likely to be lower than the
government's public estimate, according to internal projections
shared with Reuters by two sources.

Lower-than-expected production could delay India's plans to
vaccinate all its adults this year, amid fears the country will
face another surge of coronavirus infections in the winter.
India's ongoing second wave, the world's worst since the
pandemic began, has overwhelmed its health system.

The government last week publicly estimated 1.46 billion
doses of its three approved shots - AstraZeneca, Sputnik
V and Covaxin - would be made between August and December.

Production of the AstraZeneca vaccine, of which the Serum
Institute of India (SII) is the biggest maker in the world, is
expected to reach 100 million to 110 million doses a month from
July and stay at that level for the foreseeable future, a source
with knowledge of the matter said.

That would be at least 200 million doses less than the
government's public forecast of 750 million AstraZeneca doses
for the last five months of the year, a 27% shortfall.

An internal government projection for August and September
shared by a second source put the monthly number of AstraZeneca
doses at 100 million, out of 200 million for all the three
approved shots combined.

The sources declined to be named discussing a subject on
which Prime Minister Narendra Modi's government has been
criticised due to a shortage of vaccines. Immunisations have
fallen https://dashboard.cowin.gov.in sharply since an April
peak.

The Ministry of Health and Family Welfare did not respond to
queries from Reuters.

SII, which is facing raw material shortages for another
vaccine that the government is banking on, declined to comment.

A spokeswoman for Covaxin-maker Bharat Biotech said that
last month the company raised its annual production capacity to
more than 500 million doses, or about 42 million doses a month.
It has been producing about 10 million doses a month.

Dr. Reddy's Laboratories, the local distributor
for Russia's Sputnik V, did not respond to a request for
comment.

Apart from the approved vaccines, the government has also
forecast August-December production of 866 million doses of five
yet-to-be-approved vaccines. Overall, the government has pledged
to make 2.67 billion doses available this year.

SII has already halted exports until the end of the year to
meet domestic demand, in a major blow to dozens of poor
countries relying on it for supplies.

India has so far administered 187 million vaccine doses, the
most after China and the United States, but fully immunised only
about 3% of its 1.35 billion people.

(Reporting by Neha Arora and Krishna N. Das; editing by
Philippa Fletcher)

More News
18 Mar 2024 14:08

AstraZenca hails Imfinzi and Lynparza results on endometrial cancer

(Alliance News) - AstraZeneca PLC on Monday reported positive findings following the analysis of results from a phase III probe of its Imfinzi and Lynparza cancer treatments.

Read more
14 Mar 2024 10:01

TOP NEWS: AstraZeneca buys France's Amolyt Pharma for USD1 billion

(Alliance News) - AstraZeneca PLC on Thursday said it has struck a deal to acquire Amolyt Pharma SAS, strengthening its late-stage rare disease pipeline.

Read more
14 Mar 2024 07:52

LONDON BRIEFING: Astra makes USD1.05 billion buy; Halma backs outlook

(Alliance News) - London's FTSE 100 is set to tread water after the opening bell sounds on Thursday, as investors look to a batch of US data to come in the early afternoon.

Read more
14 Mar 2024 07:16

AstraZeneca snaps up rare disease specialist Amolyt for $1.05bn

(Sharecast News) - Biopharma giant AstraZeneca has announced the acquisition of French biotech firm Amolyt Pharma for up to $1.05bn to beef up its late-stage rare disease pipeline.

Read more
8 Mar 2024 06:00

Astra, Sanofi's antibody 90% effective against RSV in infants - CDC

(Alliance News) - A new treatment for infant respiratory syncytial virus, RSV, – a leading cause of severe illness in US babies – is 90% effective in preventing hospitalization, health authorities said Thursday.

Read more
6 Mar 2024 14:40

UK BUDGET: Some tax cuts but vapes, tobacco and non-doms targeted

(Alliance News) - A cut to national insurance, stamp duty relief as well as a freeze on fuel and alcohol duties were among the marquee tax measures that UK Chancellor Jeremy Hunt announced in his budget on Wednesday.

Read more
5 Mar 2024 14:24

AstraZeneca's breast cancer treatment blocked for NHS use in England

(Alliance News) - A treatment that extends the life of people with advanced breast cancer has been blocked for NHS use in England in a move that potentially impacts thousands of patients.

Read more
4 Mar 2024 09:31

AstraZeneca and Daiichi Sankyo get EU approval for cancer treatment

(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd on Monday said that the European Medicines Agency has approved two marketing authorisation applications for their datopotamab deruxtecan in two types of cancer.

Read more
4 Mar 2024 07:18

AstraZeneca's chemo replacement treatment moves closer to EU approval

(Sharecast News) - European regulators have validated two marketing authorisation applications (MMAs) for AstraZeneca, as the biopharma giant's datopotamab deruxtecan chemotherapy replacement treatment comes one step closer to receiving the green light to treat two types of cancer.

Read more
26 Feb 2024 08:51

AstraZeneca's Voydeya treatment recommended for EU approval

(Alliance News) - AstraZeneca on Monday announced further support from regulators for its first-in-class blood disease treatment.

Read more
26 Feb 2024 07:22

AstraZeneca's blood-disorder drug recommended for EU approval

(Sharecast News) - European regulators has given the green light to AstraZeneca's blood-disorder drug Voydeya, the biopharma giant announced on Monday.

Read more
22 Feb 2024 17:36

EARNINGS AND TRADING: Astra closes Gracell buy, Amicorp "on track"

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Wednesday and Thursday and not separately reported by Alliance News:

Read more
20 Feb 2024 10:29

AstraZeneca acquires US-based biopharmaceutical company

(Sharecast News) - Drugmaker AstraZeneca revealed late on Monday afternoon that it had successfully completed its acquisition of US-based biopharmaceutical company Icosavax.

Read more
20 Feb 2024 09:40

LONDON BROKER RATINGS: JPMorgan cuts Airtel Africa price target by 28%

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
19 Feb 2024 16:51

LONDON MARKET CLOSE: Europe lacks direction on quiet Monday

(Alliance News) - European markets lacked direction on Monday, after a quiet day as the US markets celebrated George Washington's birthday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.